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The calcium-sensing receptor (CaSR) is the principal regulator of the secretion of parathyroid hormone and 
plays key roles in extracellular calcium (Ca2+o) homeostasis. It is also thought to participate in the development 
of cancer, especially bony metastases of breast and prostate cancer. However, the expression of CaSR has not 
been systematically analyzed in prostate cancer from patients with or without bony metastases. By comparing 
human prostate cancer tissue sections in microarrays, we found that the CaSR was expressed in both normal 
prostate and primary prostate cancer as assessed by immunohistochemistry (IHC). We used two methods to 
analyze the expression level of CaSR. One was the pathological score read by a pathologist, the other was the 
positivity% obtained from the Aperio positive pixel count algorithm. Both of the methods gave consistent results. 
Metastatic prostate cancer tissue obtained from bone had higher CaSR expression than primary prostate cancer 
(P <0.05). The expression of CaSR in primary prostate cancers of patients with metastases to tissues other than 
bone was not different from that in primary prostate cancer of patients with or without bony metastases (P 
>0.05). The expression of CaSR in cancer tissue was not associated with the stage or status of differentiation of 
the cancer. These results suggest that CaSR may have a role in promoting bony metastasis of prostate cancer, 
hence raising the possibility of reducing the risk of such metastases with CaSR-based therapeutics. 
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Introduction 
The calcium (Ca2+)-sensing receptor (CaSR) plays a 
central role in calcium homeostasis by sensing small 
changes in the level of extracellular calcium (Ca2+o) and 
regulating parathyroid hormone (PTH) secretion and renal 
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calcium excretion so as to normalize Ca2+o. Naturally 
occurring mutations cause familial hypocalciuric 
hypercalcemia (FHH) [1], neonatal severe 
hyperparathyroidism (NSHPT) [2] and autosomal dominant 
hypocalcemia with hypercalciuria (ADHH) [3]. The CaSR 
was first cloned from bovine parathyroid glands [4] and 
belongs to class C of the G protein-coupled receptors 
(GPCR). CaSR also has been suggested to modulate 
adipocyte function [5], carcinogenesis [6], insulin secretion 
[7], mineralization of the bony matrix [8] and pathological 
calcification [9], etc. Recently, much more attention has 
been paid to possible roles of CaSR in various types of 
cancer, including colon cancer [10, 11], breast cancer [12, 13], 
prostate cancer [14, 15], ovarian cancer [16], Leydig cell 
cancer [17], gastric cancer [18], insulinoma [19], and 
glioblastoma [20].  
In breast and prostate cancer, CaSR has been suggested 
to participate in bony metastasis. It has been implicated in 
a vicious cycle of bony metastases through its modulation 
of parathyroid hormone related peptide (PTHrP) secretion 
by cancer cells [21]. Mihai et al. found that most breast 
cancer patients with a high expression of CaSR in 
malignant tissue obtained from the breast had bony 
metastases. They suggested that CaSR can serve as a 
biomarker to predict the potential risk of bony metastasis 
in breast cancer patients [22]. Liao et al. found that PC-3 
prostate cancer cells (originally obtained from a bony 
metastasis) have higher levels of CaSR mRNA than 
LNCaP cells (obtained from a lymph node). Increasing the 
extracellular calcium concentration stimulates growth of 
PC-3 cells but not of LnCaP cells [23]. Knockdown of CaSR 
expression reduces growth of PC-3 cells both in vitro and 
in vivo in a murine model of prostate cancer metastasis [23]. 
However, a direct comparison of CaSR expression level in 
the bony metastases with that in the primary cancers in 
prostate is still lacking. Therefore, the relative levels of 
CaSR expression in primary prostate cancers and in 
metastases to bone and other sites as well as the associated 
implications for the metastatic process are not clear. 
In this study, we performed immunohistochemistry 
(IHC) to detect CaSR expression in various benign and 
malignant prostatic tissues on human prostate cancer tissue 
microarrays. Our results identified a higher expression 
level of CaSR in bony metastases of prostate cancer than 
that in specimens of primary prostate cancer.  
Materials and Methods 
Tissue microarrays  
Tissue arrays containing both prostate cancer tissue and 
normal prostate tissue (PR807 and PR955) were purchased 
from the Biomax Company (Rockville, MD 
www.biomax.us). The tissue samples, including (1) 
normal prostate tissue, (2) primary prostate cancer tissue 
in patients with or without bony metastases, (3) prostate 
cancer tissue from bony metastases, and (4) prostate 
cancer tissue from abdominal wall metastases in two tissue 
microarrays, which were combined to enlarge the sample 
size. Altogether, there were 24 samples of normal prostate 
tissue, 108 samples of primary prostate cancer tissue (i.e., 
obtained from the prostate gland), and 4 samples of 
prostate cancer tissue obtained from bony metastases 
(Table 1). Among the 108 prostate cancer patients 
represented by the two arrays in which cancer tissue was 
obtained from the prostate, 12 of them had coexistent bony 
metastases while 96 of them did not. Tissue specimens 
were not available from the bony metastases in these 12 
patients.  
Immunohistochemistry (IHC) 
The slides were first deparaffinized by heating at 60°C 
for 2 hours. Then they were boiled in 10 mM citrate 
sodium solution (pH 6.0) for 10 min for antigen retrieval, 
followed by incubation in 3% H2O2 for 5-10 min to block 
endogenous peroxidase. After blocking in normal goat 
serum for 20 min, the slides were incubated with rabbit 
polyclonal anti-CaSR antibody raised against a synthetic 
Fig 1. Examples of IHC staining of CaSR in tissue 
microarrays. Four groups of tissues are shown: normal prostate 
tissue, primary prostate cancers in patients with bony metastasis, 
primary prostate cancers in patients without bony metastasis, 
and prostate cancer from bone. (×40). 
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peptide whose sequence is within the first third of the 
receptor’s N-terminal extracellular domain (Sigma, St. 
Louis, MO) at 4°C overnight. The specificity of the 
antibody was documented by negative control IHC 
(Supplemental Figure 1) (i.e., by omitting the first 
antibody) and the western blot (Supplemental Figure 2) 
asdescribed in Results. Biotinylated anti-rabbit antibody 
was used as secondary antibody. Staining was visualized 
using 3, 3'-Diaminobenzidine (DAB) tetrahydrochloride, 
and slides were counterstained with hematoxylin. 
Analysis of IHC staining 
The tissue microarrays were read by a pathologist (B.L.) 
blinded to the identity of the tissue sections. The staining 
intensity in any given tissue section was given a grade of 
1, 2 or 3. A higher grade indicates a higher intensity of 
staining. The area ratio stands for the percentage of the 
area stained for CaSR over the total epithelial cellular area. 
The final pathological score was obtained by multiplying 
the intensity grade by the area ratio. The tissue microarray 
was also scanned using a Hamamatsu/Olympus 
Nanozoomer 2.0HT whole slide image scanner 
(Hamamatsu Photonics K.K., Hamamatsu, SZK). The 
whole slide image was viewed in the Aperio ImageScope 
program (Vista, CA) and analyzed with the Aperio 
positive pixel count algorithm similar to methods 
previously described [24]. The default hue (brown) for the 
positive pixel count algorithm was used. The positivity 
(number of positive pixels over total number of pixels) of 
Fig 2. Pathological score and positivity% for CaSR expression in each group, as quantitated in 
prostate tissue microarrays. A: Comparison of pathological scores of normal prostate tissue, primary 
prostate cancer tissue, and prostate cancer tissue from bone. B: Comparison of pathological scores of 
primary prostate cancer tissue from patients with bony metastasis and primary prostate cancer tissue from 
patients without bony metastasis. C: Comparison of positivity% of normal prostate tissue, primary prostate 
cancer tissue, and prostate cancer tissue from bone. D: Comparison of positivity% of primary prostate 
cancer tissue from patients with bony metastasis and primary prostate cancer tissue from patients without 
bony metastasis. 
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 each sample was obtained for statistical analysis. 
Western Blot 
Cell lysates of cells were extracted and loaded onto an 
SDS-PAGE gel. After electrophoresis, equal amounts of 
protein from each sample were transferred to a 
nitrocellulose membrane. Then the membrane was 
blocked, incubated with Sigma anti-CaSR antibody and 
then secondary antibody sequentially. The protein bands 
were then visualized using an enhanced 
chemiluminescence reaction system (Bio Rad, Hercules, 
CA). 
Statistical analysis 
Statistical analyses of differences between groups were 
carried out by R software (R Development Core Team) 
using Student’s t test, the Wilcox test, or the Kolmogorov-
Smirnov test according to whether the samples were 
normally distributed or not. If both groups were normally 
distributed with the same variance, Student’s t test was 
used. If neither of the two groups had a normal 
distribution, the Wilcoxon test was used. If one group was 
normally distributed but the other was not, the 
Kolmogorov-Smirnov test was used. A value of P < 0.05 
was taken as indicating a statistically significant 
difference. All of the tests are two-sided. Pearson’s 
correlation was used to analyze the correlation among 
groups. P < 0.05 was taken to indicate a statistically 
significant correlation.  
Results  
Patient information 
Figure 1 and Supplemental Figure 3 shows normal 
prostate tissue with a regular glandular structure.  CaSR 
is expressed both in the cell membrane and in the 
cytoplasm of all of the epithelial cells. Primary prostate 
cancer tissue also expresses CaSR in all of the cancer cells 
with the same cellular localization, regardless of bony 
metastases or not. Prostate cancer tissue obtained from 
bone does not typically have a glandular structure, and the 
cancer cells cluster together, expressing much more CaSR 
than in prostate cancer sections obtained from the prostate 
or from non-bony metastases, as shown by the deep brown 
color in the bony metastases. Two cases of prostate cancer 
tissues obtained from the abdominal wall also did not have 
a glandular structure but show less staining than the cancer 
tissues obtained from bone.  
CaSR expression levels in patient tissues were analyzed 
using two complementary methods. As shown in Table 1, 
the median pathological score of normal prostate tissue 
was 180 with a 25th percentile of 95 and 75th percentile of 
214, and the median pathological score of all prostate 
cancer tissue samples obtained from prostate was 190 with 
a 25th percentile of 115 and 75th percentile of 240. All of 
the 4 prostate cancer tissues obtained from bone had the 
same pathological score of 300 (i.e., all had intensity 
grades of 3 with 100% of the cells staining positive for 
CaSR). Two cases of prostate cancer tissues obtained from 
the abdominal wall had a score of 120.  
The Aperio positive pixel count algorithm was applied 
to measure the areas and intensities in IHC results [24, 25]. 
The positivity%, which describes the number of positive 
pixels over the total number of pixels of each sample, was 
used, in addition to the use of the pathological score, to 
analyze the expression level of CaSR. The semi-
quantitative values obtained by this method are 
summarized in Table 2 for detailed comparison. The 
median positivity% of normal prostate tissue was 0.07 
with a 25th percentile of 0.03 and 75th percentile of 0.14, 
and the median positivity% of all prostate cancer tissue 
samples obtained from prostate was 0.07 with a 25th 
percentile of 0.03 and 75th percentile of 0.16. All of the 4 
prostate cancer tissues obtained from bone had a 
positivity% of around 0.39. Therefore the use of these two 
different methods yielded quite consistent results, showing 
a significant correlation by linear regression between 
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pathological score and image analysis (Supplemental 
Figure 4). 
Statistical analysis of the pathological scores showed 
that there was no difference in CaSR expression between 
the normal prostate tissues and the primary prostate cancer 
tissues (Fig. 2A) (P = 0.65). There were only 4 samples of 
prostate cancer tissue metastatic to bone, and 
consequently, the Kolmogorov-Smirnov test was used, 
since it can be employed with small sample sizes. The 
metastatic prostate cancer tissues obtained from bone have 
higher CaSR expression than the prostate cancer 
specimens obtained from prostate (P = 0.001) or the 
normal prostate tissue (P = 0.004).  Among the 108 
samples of prostate cancer obtained from prostate, 12 
samples were from patients having bony metastasis (tissue 
from the bony metastases of these patients were not 
available), and these had the same CaSR expression in the 
primary prostate cancer specimens as that in the 96 
samples from primary prostate cancer of patients having 
no bony metastases (P = 0.67). (Figure 2B)   
The positivity% results are shown in Figure 2 C and D. 
The conclusions are the same. There was no difference in 
CaSR expression between the normal prostate tissues and 
the primary prostate cancer tissues (P = 0.97). The 
metastatic prostate cancer tissues obtained from bone have 
higher CaSR expression than the prostate cancer 
specimens obtained from prostate (P = 0.003) or the 
normal prostate tissue (P = 0.003). Samples from primary 
prostate cancer tissue of patients having bony metastasis 
had the same CaSR expression as the primary prostate 
cancer samples from patients having no bony metastases 
(P = 0.07). 
Correlation of CaSR expression with cancer stage 
The tissue array included 29 cases of stage 2 cancer, 44 
cases of stage 3 cancer, and 33 cases of stage 4 cancer. The 
scatter plot in Figure 3A shows that there is no correlation 
between the pathological score for the CaSR and stage of 
the cancer (R2 = 0.011, P = 0.54). The data on the stages 
of the patient’s cancers are shown in Supplemental Table 
1. The positivity% results also showed that there is 
likewise no correlation (R2 = 0.007, P = 0.41) as in Figure 
Fig 3. Relationship between pathological score and positivity% for CaSR expression and cancer progression stage, Gleason 
score, and PSA concentration in blood. A: Relationship between pathological score of CaSR expression in primary prostate cancers 
and cancer stages. B: Relationship between pathological score of CaSR expression in primary prostate cancers and Gleason Score. C: 
Relationship between pathological score of CaSR expression in primary prostate cancers and PSA concentration. D: Relationship 
between positivity% of CaSR expression in primary prostate cancers and cancer stages. E: Relationship between positivity% of CaSR 
expression in primary prostate cancers and Gleason Score. F: Relationship between positivity% of CaSR expression in primary prostate 
cancers and PSA concentration. 
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3 D. 
Correlation of CaSR expression with Gleason score    
Cancers with a higher Gleason score are more 
aggressive and have a worse prognosis. The scatter plot in 
Figure 3B shows that there is no correlation between the 
pathological score for CaSR expression and the Gleason 
score (R2 = 0.003, P = 0.08). Information about the patients 
on whom a Gleason score was available is shown in 
Supplemental Table 2. There is also no correlation 
between Gleason score and positivity% (R2 = 0.009, P = 
0.31) as shown in Figure 3 E. 
Correlation between CaSR expression and prostate 
specific antigen (PSA) concentration    
PSA, secreted by the epithelial cells of the prostate 
gland, is often elevated in the presence of prostate cancer 
or other prostate disorders. The normal PSA levels should 
be less than 4 ng/mL. The scatter plot in Figure 3C shows 
that there is no correlation between the pathological score 
for CaSR expression and the PSA concentration in blood 
(R2 = 0.013, P = 0.07). Information about the patients in 
whom PSA values were available is shown in 
Supplemental Table 3. There is also no correlation 
between PSA and positivity% (R2 = 0.075, P = 0.05) as 
shown in Figure 3 F.  
Discussion 
In this study, higher expression level of CaSR were 
found to be associated with the metastatic prostate cancer 
tissues obtained from bone rather than primary prostate 
cancer tissues or normal prostate tissues, while no 
significant difference in CaSR expression between normal 
prostate tissue and primary prostate cancer tissue was 
observed. The metastatic prostate cancer tissues studied 
here that were obtained from bone have higher CaSR 
expression than primary prostate cancer tissues. For the 
second tissue microarray (designated PR955 by the 
supplier), most of the tissues were obtained from prostate. 
Some were obtained from metastatic sites: 6 from bone 
and 2 from the abdominal wall. The samples of prostate 
cancer obtained from bone in these arrays are very scarce 
and fragile. Sections from two such bony metastases were 
damaged. Therefore, only four were available for 
statistical comparison with the staining from the other 
tissues due to limitations of patient sample availability. 
However, these four prostate cancer tissues obtained from 
bone all showed the highest level of CaSR expression 
among the tissues studied here, as reflected by the largest 
possible pathological score of 300 for each specimen. 2 
metastases from the abdominal wall both had scores of 
only 120. This may suggest that high expression of CaSR 
in the cancer tissue from bone is a consequence of their 
localization in the bony environment, e.g., expression of 
the CaSR may be upregulated by factors in the bony 
microenvironment (see below). It is also possible that bone 
selects for metastatic cells with high CaSR expression and 
resultant increased potential to metastasize to bone 
because bone is a “fertile field” [26] for them when they 
express a high level of CaSR.  
Importance of bone environment 
Bone is a favored metastatic site for some cancer cells 
[27]. These metastatic sites are characterized by high rates 
of bone turnover [28], with continuous breakdown of bone 
by osteoclasts, followed by replacement of the missing 
bone by osteoblasts. In some active lacunae where bone 
resorption is taking place, the extracellular calcium level 
can reach as high as 8-40 mmol/L [29]. The high calcium 
concentration within this microenvironment could induce 
the expression of the CaSR in cancer cells. High 
concentrations of calcium and calcimimetics (i.e., 
allosteric CaSR activators) have, in fact, been shown to 
upregulate expression of the CaSR in normal tissues, such 
as parathyroid gland [30, 31]. Elevated extracellular calcium 
concentrations stimulate parathyroid hormone related 
peptide (PTHrP) production by prostate cancer cell lines 
[32], which could increase bone resorption near bony 
metastases of prostate cancer [33], thereby producing a 
favorable environment for tumor growth and providing a 
growth advantage for metastatic cancer cells having high 
CaSR expression. 
There is abundant literature addressing possible targets 
for the treatment of prostate cancer [34, 35]. The seed and 
soil theory is a popular one [36]. Cancer cells are regarded 
as the seeds and the bony environment as the soil. Some 
believe that the therapeutic target should be the seed. From 
the point of view of our study, treatments targeting both 
the seed (e.g., prostate cancer cells with high CaSR 
expression) and soil (i.e., high local levels of Ca2+o in 
bone) could be a better therapeutic direction in the clinic. 
That is, a therapeutic approach combining inhibition of 
bone resorption using a bisphosphonate [37], for example, 
and suppression of CaSR activity with a calcilytic, e.g., a 
negative allosteric modulator of the receptor [38]. While 
such a combined approach has not been reported to our 
knowledge, decreasing the level of expression of the CaSR 
in PC-3 cells in a murine model of prostate cancer 
metastasis to bone, reduced the metastatic burden in bone 
[23].  
Comparison with other studies 
CaSR is considered to be an important factor in bony 
metastases of some types of cancer. Breast cancer tissues 
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from patients with bony metastases have higher expression 
of CaSR than that of breast cancer from patients without 
bony metastases. In our study, we didn’t see any 
differences between CaSR expression in the primary 
prostate cancers of patients with bony metastases and that 
in the primary prostate cancers that had not metastasized 
to bone. This might be due to the CaSR having different 
functions in different types of cancer [39, 40]. Huang et al. 
demonstrated that CaSR expression was significantly 
higher in more tumorigenic prostate cancer cell lines and 
in prostate cancer tissue specimens than in the normal 
prostate cells [41]. However, this study did not use IHC to 
detect the expression of CaSR protein in situ, but extracted 
the protein from the normal tissue and cancer tissue then 
performed western blot analysis. The number of tissue 
specimens examined was also small. 
Adams, et al. reported that hematopoietic stem cells 
engraft in bone, at least in part, because of CaSR. 
Hematopoietic stem cells from CaSR-/- mice exhibited 
diminished adhesion to extracellular matrix proteins, even 
though they were normal in their capacities to 
differentiate, migrate and home to bone [42]. Therefore, if, 
as we have suggested, CaSR expression increases after 
prostate cancer cells arrive at bone, this increased CaSR 
could potentially enhance the capacity of cancer cells to 
localize in the bone by a similar mechanism(s). 
Conclusions  
Our tissue microarray study suggests that CaSR 
expression may increase after prostate cancer cells arrive 
at bone. This increase could result from the process of 
cancer cells adapting to the bony environment and, 
thereby, enhancing their capacity to colonize in bone. We 
cannot exclude, however, the possibility that small 
numbers of prostate cancer cells with high CaSR 
expression have greater metastatic potential for bone 
rather than the remaining prostate cancer cells localized in 
prostate. Stimulation of PTHrP secretion by the high level 
of CaSR expressed by this subpopulation of cells might 
enhance their capacity to establish metastases in bone. 
Given the limited number of prostate cancer tissues 
obtained from bony metastases studied here due to 
difficulties in obtaining such samples, it would be 
important to extend the study in the future to additional 
cases of bony metastases of prostate cancer.  
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Suppl. Table 1. Pathological tumor (T) stage and positivity% for expression of CaSR in primary prostate cancer 
tissues of patients with different stages of prostate cancer in array PR955 
T Stage Cases (N) Pathological Score (%) 
(intensity multiplied by area) 
Median (25th, 75th percentiles) 
Positivity (%) 
Median 
(25th, 75th percentiles) 
2 29 180 (85,200) 0.06 (0.03,0.13) 
3 44 190 (158,255) 0.06 (0.03,0.14) 
4 33 180 (160,200) 0.08 (0.05,0.16) 
The correlation P value for stage and pathological score is 0.54. The correlation P value for stage and positivity is 0.41. 
Suppl. Table 2. Pathological scores and positivity% for expression of CaSR in primary prostate cancer tissues of 
patients with different Gleason scores in array PR955 
Gleason 
score 
Cases (N) Pathological Score (%) 
(intensity multiplied by area) 
Median(25th, 75th percentiles) 
Positivity (%) 
Median 
(25th, 75th percentiles) 
4 1 200 0.26 
5 1 170 0.25 
6 12 175 (89,221) 0.09 (0.04,0.23) 
7 34 195 (160,255) 0.08 (0.04,0.14) 
8 16 190 (93,214) 0.10 (0.02,0.17) 
9 32 185 (150,200) 0.05 (0.03,0.10) 
10 11 180 (145,200) 0.15 (0.04,0.24) 
The correlation P value for Gleason score and pathological score is 0.08. The correlation P value for Gleason score and 
positivity is 0.31. 
Suppl. Table 3. Pathological scores and positivity% for expression of CaSR in primary prostate cancer tissues of 
patients with different PSA concentrations in array PR955 
PSA(ng/mL) Cases (N) Pathological Score (%) 
(intensity multiplied by area) 
Median (25th, 75th percentiles) 
Positivity (%) 
Median 









4-10 9 200 (160,200) 0.03 (0.02,0.04) 
10-20 20 185 (120,200) 0.06 (0.04,0.14) 
20-40 13 255 (190,285) 0.12 (0.08,0.16) 
>40 10 198 (190,253) 0.10 (0.03,0.12) 
The correlation P value for PSA and pathological score is 0.07. The correlation P value for PSA and positivity is 0.05. 
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Suppl. Figure 1. IHC staining of CaSR in prostate tissue with 
Sigma anti-CaSR antibody (right) and negative control (left). 
(×10) 
 
Suppl. Figure 2. Western Blot of CaSR expression in 
prostate cancer cell line, PC-3 cells, using Sigma anti-
CaSR antibody. GAPDH was detected as a loading control. 
 
Suppl. Figure 3. IHC staining of CaSR in prostate tissue 
microarray PR955. Normal prostate tissue: H1-H11 and G9-G12 
Primary prostate cancer: A1-A12, B1-B12, C1-C12, D1-D12, E1-
E12, and F1-F12. Prostate cancer from bone: G3-G8 (G5 and G6 
were damaged). Prostate cancer from abdominal wall: G1-G2. (×4) 
 
Suppl. Figure 4. Correlation between pathological score and 
positivity%. (R2 = 0.35, P = 0.001) 
 
